Highlights from ThoughtSpot 2022

Researchers explored patients with type 1 diabetes and overweight or obesity to understand the efficacy and safety of GLP-1s as adjunctive therapies.

NBC News Medical Analyst Vin Gupta, MD, joins Drug Topics at NCPDP 2025 to discuss the technological evolution of the pharmacy profession.

In an abstract presented at the American Diabetes Association 85th Scientific Sessions, researchers tested the effectiveness of an AI-driven program for improving glycemic control.

Drug Topics wraps up a great week in Las Vegas at McKesson ideaShare.

An ambulatory care pharmacist program in Washington State dramatically improved diabetes management by reducing A1c levels, increasing medication adherence, and providing comprehensive patient education.

Results from the CATALYST trial showed patients who received mifepristone had a mean HbA1c reduction of 1.47%,